Evidence map›Paper›PMID 31271211›Full record

ReviewNicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco2020

Defining and Measuring Abstinence in Clinical Trials of Smoking Cessation Interventions: An Updated Review.

Megan E Piper, Christopher Bullen, Suchitra Krishnan-Sarin, Nancy A Rigotti, Marc L Steinberg, Joanna M Streck, Anne M Joseph

Open access · greenAbstract readReview
In one paragraph

Review in Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 141 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
141citing papers in PubMed, 7 pooled it
9.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

141 citing papers in PubMed, 7 syntheses or guidelines pooled it, 215 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Interventions for tobacco use cessation in people living with HIV.The Cochrane database of systematic reviews · 2024
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Cessation of Smoking Trial in the Emergency Department: Long-Term Follow-up of a Randomized Controlled Trial.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2026
    Trial
  12. Trial
  13. Trial
  14. Trial
  15. Urge Coping Mediates the Relationship Between Physical Activity and Smoking Outcomes in a Sample of Premenopausal Women Intending to Quit Smoking.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2025
    Trial
  16. Biomarkers of Nicotine and Tobacco Carcinogen Exposure in Socioeconomically Disadvantaged Black Adults Receiving a Brief Smoking Reduction Intervention.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025
    Trial
  17. The Efficacy of the SinHumo App Combined With a Psychological Treatment to Quit Smoking: A Randomized Clinical Trial.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2025
    Trial
  18. Effects of a Tailored Mobile Messaging Intervention for Indoor Tanning Cessation in Young Females: A Randomized Clinical Trial.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025
    Trial
  19. Behavioral Activation mHealth Application for Smoking Cessation: A Randomized Controlled Pilot Trial.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2024
    Trial
  20. Trial

81 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 7 institutions in 2 countries.

Megan E PiperCenter for Tobacco Research and Intervention of Wisconsin, Department of Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, WI.
Christopher BullenNational Institute for Health Innovation, School of Population Health, University of Auckland, Auckland, New Zealand.
Suchitra Krishnan-SarinDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT.
Nancy A RigottiDepartment of Medicine, Massachusetts General Hospital, Boston, MA.
Marc L SteinbergDivision of Addiction Psychiatry, Rutgers University, New Brunswick, NJ.
Joanna M StreckDepartment of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Anne M JosephDepartment of Medicine, University of Minnesota, Minneapolis, MN.
Harvard University · USMassachusetts General Hospital · USRutgers, The State University of New Jersey · USUniversity of Auckland · NZUniversity of Minnesota · USUniversity of Wisconsin–Madison · USYale University · US

Funding

Persistence Targeted Smoking Cessation in Schizophrenia (PTSC-S)R33DA041163 · NIDA · RBHS-ROBERT WOOD JOHNSON MEDICAL SCHOOL · PI STEINBERG, MARC L · 2018 to 2020
$716k
NIDA NIH HHS R33 DA041163
6 · The paper itself

Abstract

backgroundChanges in tobacco products, use patterns, and assessment technology in the last 15 years led the Society for Research on Nicotine and Tobacco (SRNT) Treatment Research Network to call for an update to the 2003 SRNT recommendations for assessing abstinence in clinical trials of smoking cessation interventions.

methodsThe SRNT Treatment Research Network convened a group of investigators with decades of experience in conducting tobacco treatment clinical trials. To arrive at the updated recommendations, the authors reviewed the recommendations of the prior SRNT Workgroup as well as current literature. Ten additional experts in the field provided feedback on this paper and these recommendations.

resultsWith respect to defining abstinence, the authors recommend: (1) continuing to use the definition of no use of combustible tobacco products (regardless of use of noncombustible tobacco products [e.g., snus] and alternative products [e.g., e-cigarettes]) and collecting additional data to permit alternate abstinence definitions; (2) no use of combustible or smokeless tobacco products; and (3) no use of combustible or smokeless tobacco products or alternative products, as appropriate for the research question being addressed. The authors also recommend reporting point prevalence and prolonged abstinence at multiple timepoints (end of treatment, ≥3 months after the end of treatment, and ≥6 months postquit or posttreatment initiation).

conclusionsDefining abstinence requires specification of which products a user must abstain from using, the type of abstinence (i.e., point prevalence or continuous), and the duration of abstinence. These recommendations are intended to serve as guidelines for investigators as they collect the necessary data to accurately describe participants' abstinence during smoking cessation clinical trials. IMPLICATIONS: This paper provides updated recommendations for defining abstinence in the context of smoking cessation treatment clinical trials.

Indexed as

Behavior TherapyClinical Trials as TopicElectronic Nicotine Delivery SystemsHumansSmoking CessationSmoking Prevention

Identifiers

PMID31271211
PMCPMC9633719
OpenAlexW2955525647

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.